I am proposing that all companies currently engaged in developing biosimilars join hands with their regulatory and scientific ...

Reported total revenue of $10.3 million and GAAP Net Income of $0.6 million, or $0.02 per diluted shareEntered into an asset purchase agreement to acquire Increlex® (mecasermin injection)Q3 2024 produ ...

Entered into an asset purchase agreement to acquire Increlex® (mecasermin injection) from Ipsen S.A. The transaction, which was announced in October, will add a high-value biologic product to the ...

Reported total revenue of $10.3 million and GAAP Net Income of $0.6 million, or $0.02 per diluted share Entered into an asset purchase agreement to acquire Increlex® (mecasermin injection ...

PARIS, FRANCE, 23 October 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its performance for the year to date and the third quarter of 2024 ...